8月20日，生物制药公司维京治疗公司（Viking Therapeutics，股票代码：VKTX）股价在盘中大涨5.05%，引起投资者广泛关注。这一涨幅主要源于该公司最新公布的肥胖药物试验结果获得分析师积极评价。
维京治疗公司的实验性减肥药VK2735在一项中期试验中表现出色，帮助患者减轻了12.2%的体重。虽然这一数据略低于华尔街最高15%的预期，但多家券商仍对该药物的前景持乐观态度。Oppenheimer分析师认为，通过剂量调整，该药物还有进一步改善的空间。BTIG则表示，尽管市场出现短暂抛售，但VK2735的"竞争定位完好无损"。
值得注意的是，17家券商中有15家给予维京治疗公司"买入"评级，显示出华尔街对该公司的强烈信心。摩根大通分析师指出，从低剂量开始逐步增加可能会带来有竞争力的耐受性，而不会对长期研究的疗效产生重大影响。这一观点进一步增强了投资者对VK2735未来发展潜力的信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.